Global Antibiotics Market Size, Share & Trends Analysis Report By Type (Branded Antibiotics, Generic Antibiotics), By Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Others),By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides, 7-ACA, Others) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) | Forecast [2024-2032] The report offers the value (in USD Billion) for the above segments.

Market Overview

The Antibiotics Market size was valued at around 50.91 billion in 2023 and is expected to reach a value of USD 75.66 Billion by 2032, at a CAGR of 5.9% over the forecast period (2024–2032).

The Forecast Period of Antibiotics Market is :

Infectious diseases are rapidly increasing, which is pushing the market upward. According to the Centres for Disease Control and Prevention, more than 31 million cases of flu were reported in the United States during the 2022–2023 flu season. Advanced products like innovative designs and growing partnerships to manufacture antibiotics are also projected to fuel further growth in the market over the forecast period. The COVID-19 pandemic also positively impacted the growth of the industry.

The research was done in order to evaluate the association of COVID-19 cases and immunization with international sales of antibiotics, according to the article in Elsevier Ltd. published on February 2023. Research states that the antibiotics were given to approximately 75% patients of COVID-19 which ultimately enhanced antimicrobial resistance. Every sale of cephalosporin, penicillin, macrolides, and tetracycline increased incrementally to pre-pandemic times till May 2022. More efforts into making high-value products are escalating market demand.

The Pew Charitable Trust reported that about forty-three compounds were in some stage of development as of December 2020 in the United States. Among them, fifteen were at the phase 1 clinical study stage, thirteen were in the phase 2 and phase 3 trial stages, and two were in FDA assessment. Among the lead candidates, about 19 of these lead candidates demonstrated activity against gram-negative Eskape pathogens. Additionally, 1 in 4 new medicines in the pipeline belong to new pharmacological classes. Major players are teaming up to share the costs of antibiotic development.

An agreement between GARDP and Mitsubishi Tanabe Pharma Corporation allows GARDP to screen over 50,000 compounds in the library at MTPC. According to an article published by the Global Antibiotic Research & Development Partnership (GARDP) Foundation in November 2022. Institute Pasteur Korea Optimised High Throughput Screen tests a selection of agents to identify new agents that exert antibacterial activity against antibiotic-resistant bacteria.". Such extreme bacterial disease, this agreement is going to assist GARDP in developing antibiotics and in the meanwhile guarantees sustainable supplies that are increasingly in-demand within the markets.

Key Findings:

• Data on antimicrobial use for 2022 was reported by 29 countries, which include two European Economic Area (EEA) countries, namely Iceland and Norway, and 27 EU member states. One country, Cyprus, reported the total consumption for both sectors together, one country, Germany, reported only community consumption, and twenty-seven countries published consumption data for the hospital and community sectors separately.
• The unit of measurement is the number of specified daily doses (DDD) per 1,000 inhabitants per day for antimicrobial usage. Both 2022 and historical data were analysed using the Anatomical Therapeutic Chemical (ATC) categorisation index with Defined Daily Doses (DDDs) 2023.
• In 2022, antibacterials for systemic use, ATC group J01 population-weighted mean daily consumption per 1,000 inhabitants across the community and hospital sectors together was 19.4 DDD in the EU. The population-weighted mean consumption in the EU for the 10-year period 2013–2022 decreased statistically significantly, though this is an enormous increase compared with 2020 and 2021. Bulgaria and Cyprus recorded a statistically significant upward trend over the past ten years.
• Slow progress towards achieving the EU's 20% reduction target by 2030 is made, evidenced by the 2.5% population-weighted mean total consumption of antibacterials for systemic use in the baseline year of 2019.
• Just 10 (36%) of the countries (one EEA and nine EU Member States) reached or exceeded the EU target in 2022 that by 2030, at least 65% of antibiotic use is from the "Access" group, as categorized by WHO's AWaRe framework for antibiotics. From 2019 onward, the share of the EU member states that reach or exceed the target of 65% has been stable.
• During the five-year period 2018–2022, there was no statistically significant trend in the overall consumption of antimycotics and antifungals for systemic use (ATC groups J02 and D01B) throughout the community and hospital sectors combined. On the other hand, parenteral amphotericin B (ATC code J02AA01) usage rose sharply.

Market Drivers

Lack of Political will by LMIC Governments

• It refers to the political will of political leaders and bureaucrats, which defines political will as "the commitment of political leaders and bureaucrats to take actions in pursuit of a set of objectives and to bear the costs of those actions over time." Political will of an incumbent government is one of the important factors determining budgetary allocations, public-private partnerships, decision-making, and inflow of finances and/or technical expertise into a country.27 Since political will encourages the preparation and implementation of NAPs on AMR, it is an important element required for LMICs to reduce improper use of antibiotics. Lack of political will in LMICs leads to an inadequately developed or no regulatory framework for prevention of AMR and misuse of antibiotics. Lack of political will is the only barrier stopping the development and implementation of NAPs in LMICs.

Key Findings:

• Co-packaged for intravenous use, XACDURO (durlobactam for injection; sulbactam for injection) received FDA approval from Innoviva Speciality Therapeutics in May 2023.
• The novel Siderophore Cephalosporin Antibacterial Drug Cefiderocol's drug application was approved for review in Taiwan in December 2022.

Market Opportunities

Growing Demand for Advanced Antibiotics to Combat Multidrug-Resistant Bacteria

• An emerging public health concern is the rise of multidrug-resistant bacteria. This situation calls for antibiotics with more advanced efficacy against such resistant pathogens. MDR bacteria are resistant to more than one antibiotic because they have been used in excess in health care and agriculture. The high rate of pathogen resistance development in response to excessive use and misapplication of available drugs necessitates the formulation of novel mechanisms of action in antibiotics to fight infections.
• The present scenario and factors influencing the healthcare space worldwide make governments and healthcare systems focus on controlling MDR outbreaks. This, in turn, presents opportunities for pharma and biotech companies to innovate in this area. The regulatory bodies are also bringing in streamlined approval pathways and incentives for next-generation antibiotics. This market dynamic not only addresses an urgent medical need but also opens avenues for companies to establish themselves as leaders in combating antibiotic resistance, thereby working toward better patient outcomes and global health security.

Market Restraining Factors

The Economics of Antibiotic Demand Failures

• The primary issue with antibiotic use from both a demand and use perspective is that the willingness (ability) to pay for antibiotics does not correspond well with their societal worth. This means that while some people are willing to pay for antibiotics when their use is of little value (either due to a lack of knowledge about their proper use or because they are used for non-medical activities with relatively low social value), others cannot afford them when their use would be highly socially valuable (usually because antibiotics are expensive or impossible to access when use would be highly efficacious). This is inefficient as well as unfair. But this is not the only market failure that leads to resistance; antibiotic use (and consequently resistance) is more common than it would be otherwise due to market failures in infection prevention, and sub optimally high resistance is also caused by incorrect internalisation of the cost of environmental pollution from pharmaceutical production..

Segmentation Analysis

The market scope is segmented because of by Type, by Action Mechanism, by Drug Class.

• By Type

Based on the Type of the market is segmented into Branded Antibiotics, Generic Antibiotics.

In 2023, the market share of the generic antibiotics market was the highest. The factors contributing to the leading position of this market include the low price of generic formulations, the huge number of manufacturers that gives a significant bargaining power to the consumer, and the conducive regulatory environment. Favourable government initiatives towards the encouragement of generic preparations and easy access to generic pharmaceuticals are also fuelling the growth of the segments.

The strong research pipeline, growing demand for new and innovative antibiotics, and growing attention from major players to fortify their product lines and distribution systems ensure a substantial compound annual growth rate for the branded antibiotics market during the forecast period of 2024-2030. For instance, in the U.S. Alembic Pharmaceuticals has received Food and Drug Administration approval of the Fesoterodine Fumarate Extended-Release pills in January 2023 in the dosages of 4 and 8 mg. Such factors are responsible for its increasing market demand.

• By Action Mechanism

Based on the Action Mechanism of the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, Others.

Cell wall synthesis inhibitors was the market leader in 2023. The cell wall synthesis inhibitors are mainly used as antibiotics because they have a broad spectrum of activity against both gram-positive and gram-negative bacteria. The drugs inhibit the production of the peptidoglycan layer, which is integral to the structural function of the cell wall. It includes cephalosporins, penicillin’s, carbapenems, and others. This segment is going to grow extensively over the course of the projection period due to increased government funding and research activities.

According to the U.S. FDA article, the Centre for Drug Evaluation and Research (CDER) approved 37 new drugs in 2022 as either novel molecular entities (NMEs) under New Drug Applications (NDAs) or new useful biological products under Biologics License Applications (BLAs). Due to an upsurge in R&D activities and product launches by industry players, the RNA synthesis inhibitors category is expected to witness a significant compound annual growth rate over the forecasting years. In addition, based on an article published by the Royal Society of Chemistry in 2022, the market for this category is also being driven by the two known and clinically approved families of natural compounds that inhibit RNAP: rifamycins and fidaxomycin.

• Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America dominated the market for global antibiotics due to well-established infrastructure, significant research and development activities, and prevalence of bacterial infection in the region. The regional companies are associated with major pharmaceuticals that focus on developing novel antibiotics, supported by government and regulatory bodies in their respective country. Some of the initiatives supporting the market in this region are antimicrobial stewardship programs and high healthcare expenditure. Advanced diagnostic tools, coupled with the growing awareness among healthcare professionals and patients regarding antibiotic resistance, support this region to lead the market. The United States is a significant contributor to this market growth, mainly because of its high focus on the fight against multidrug-resistant bacteria.

The antibiotics market is expected to develop at the quickest rate in the Asia-Pacific region. A growing population, increase in the incidence of infectious diseases, and the development of health infrastructure in developing countries like China and India are the main growth drivers. The high rates of bacterial illnesses, especially in rural and underdeveloped areas, are driving the need for antibiotics in the region. The market also expands at a faster pace due to the growth of healthcare spending, expansion of pharmaceutical production, and government programs for improving access to antibiotics. Thus, Asia-Pacific becomes the indispensable area for the further growth of the antibiotics market.

List of Companies Profiled

• AbbVie, Inc.
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals, Inc.
• Viatris, Inc.
• Melinta Therapeutics LLC
• Cipla, Inc.
• Shionogi & Co., Ltd.
• KYORIN Pharmaceutical Co., Ltd.
• GSK Plc
• Nabriva Therapeutics PLC

Key Industry Developments

In July 2023, Orchid Pharma, a pharmaceutical firm based in India, entered into a technology transfer agreement with a biotechnology company for its fermentation based on the "7ACA" project in the production-linked incentive scheme

In April 2023, Baxter International Inc. launched ZOSYN in the U.S. (piperacillin and tazobactam) Injectio.

Report Coverage

The report will cover the qualitative and quantitative data on the global Antibiotics Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Global Antibiotics Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Antibiotics market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Antibiotics. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Antibiotics companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Antibiotics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Antibiotics Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Antibiotics Market valued?
• Which region has the largest share in 2024 for the global Antibiotics Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Antibiotics Market

• Historic year: 2019- 2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Billion

Antibiotics Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: